Bavar­i­an Nordic makes plans to sub­mit chikun­gun­ya vac­cine for ap­proval af­ter sec­ond pos­i­tive PhI­II tri­al read­out

Bavar­i­an Nordic’s chikun­gun­ya vac­cine has suc­ceed­ed in a sec­ond Phase III tri­al in ado­les­cents and adults be­tween 12 years old and 64 years old, the Dan­ish com­pa­ny said Sun­day.

In the 3,254-pa­tient tri­al, there were “sig­nif­i­cant neu­tral­iz­ing an­ti­bod­ies” in 97% of pa­tients two weeks af­ter vac­ci­na­tion and 86% of pa­tients had sero­pro­tec­tive lev­els of neu­tral­iz­ing an­ti­bod­ies six months af­ter vac­ci­na­tion, hit­ting the co-pri­ma­ry end­points of the study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER